• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Agilent Automated Workflows at SLAS2025: Connecting with Confidence

    1/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Building the lab of the future today by enhancing lab productivity with robust and reliable automation technology

    Agilent Technologies Inc. (NYSE:A) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes.

    Automation is becoming increasingly critical for labs as they navigate the competitive landscape. Agilent's automation solutions include sample and standard preparation, auto dilution, sample delivery, and washout. These solutions cover cell analysis, genomics, proteomics, biomolecule analysis, and mass spectrometry in regulated and non-regulated labs. By automating these tasks, scientists and lab technicians can focus on more important work. Automated sample preparation becomes more manageable, accurate, and consistent, which increases data quality and reduces the time needed to get results, ultimately leading to better decisions.

    "Connecting automated solutions to your workflows allows for current manual processes to be a thing of the past, significantly boosting lab productivity, making lab managers' days easier and giving back time to focus on other tasks," stated Lars Kristiansen, general manager of Agilent's Automation Solutions Business. "SLAS is the perfect platform for us to showcase how our cutting-edge automation solutions push the boundaries of what's possible. We're dedicated to delivering innovative workflow solutions that advance automation and drive customer success."

    SLAS attendees are invited to visit exhibit booth #1529 to discover how Agilent's automation solutions can confidently connect and enhance their labs. Highlighted innovations will include:

    • NovoCyte Opteon Spectral Flow Cytometer ‒ The NovoCyte Opteon boasts up to 5 lasers and 73 detectors, a proprietary optics design, and advanced electronics, enabling it to deliver data with high resolution and sensitivity.
    • SureSelect Cancer CGP Assay ‒ The SureSelect Cancer CGP Assay offers comprehensive genomic profiling for solid tumors, detecting various somatic variants and immuno-oncology biomarkers.
    • ePrep Partnership ‒ Agilent has partnered with ePrep to offer streamlined end-to-end workflow solutions for GC/MS and LC/MS analyses.
    • Avida ‒ Agilent Avida offers high-performance target enrichment for DNA sequencing, optimized for sensitive variant detection and streamlined workflows.

    A Solutions Spotlight Presentation "Revolutionizing Viral Infectivity Assays: High-Resolution Automated Cell Imaging Meets AI/ML Analysis" will be held Monday, January 27, from 11:30 AM - 11:50 AM PT in the SLAS Solutions Spotlight Theater (Booth #2907) highlighting the Agilent BioTek Cytation platform. Presenters include Ilya Goldberg, Ph.D., Chief Scientific Officer at ViQi, and Joe Clayton, Ph.D., Director of Application Development and Technical Marketing, in the Cell Analysis Division at Agilent.

    Additionally Agilent will participate in a roundtable discussion entitled "Robotic automation is the gateway to the Lab of the Future," hosted by ABB Robotics. The conversation will highlight how robots can unlock new possibilities in the lab, and explore some of the challenges that can be solved using robots. The roundtable will be held on Tuesday, January 28, from 8:30 AM - 10:00 AM PT in Room #26A at the conference venue, and is open to all SLAS attendees.

    Agilent is a proud Diamond Sponsor of the SLAS2025 International Conference & Exhibition, highlighting Agilent's commitment to advancing laboratory automation and life sciences discovery.

    About Agilent Technologies

    Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250124528121/en/

    Media Contact

    Naomi Goumillout

    Agilent Technologies

    +1.978.314.1862

    [email protected]

    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy
    HSBC Securities
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    12/9/2025$170.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    10/8/2025$165.00Buy
    Rothschild & Co Redburn
    10/8/2025$170.00Neutral → Buy
    UBS
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    More analyst ratings

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

    Award honors leadership in sustainable laboratory practices and circular economy advancement Agilent Technologies Inc. (NYSE:A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent's trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and contributing to the circular use of scientific equipment. In 2025, Boehringer Ingelheim led all partners in responsible trade‑in activity, ensuri

    2/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

    Approval expands first-line PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression at the time of diagnosis, supporting informed treatm

    2/11/26 6:45:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00

    1/5/26 8:23:48 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Equal Weight to Overweight and set a new price target of $165.00

    12/15/25 8:55:45 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by V.P., Corporate Controller Gonsalves Rodney

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    1/8/26 4:05:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dolsten Mikael sold $389,511 worth of shares (2,600 units at $149.81), decreasing direct ownership by 34% to 4,973 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/3/25 4:04:44 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Zhang Jianmiao Mike covered exercise/tax liability with 208 shares, decreasing direct ownership by 2% to 11,639 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/1/25 4:36:53 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    SEC Filings

    View All

    SEC Form DEFA14A filed by Agilent Technologies Inc.

    DEFA14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:10:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Agilent Technologies Inc.

    DEF 14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:00:39 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form PRE 14A filed by Agilent Technologies Inc.

    PRE 14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    1/23/26 7:00:20 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    7/22/24 9:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Financials

    Live finance-specific insights

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    2/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Reports Fourth-Quarter Fiscal Year 2025 Financial Results

    Delivers solid results in Q4, initiates FY26 guidance Fourth-quarter fiscal year 2025 Revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% on a core(1) basis compared with the fourth quarter of 2024. GAAP net income of $434 million; earnings per share (EPS) of $1.53, up 25% from the fourth quarter of 2024. Non-GAAP(2) net income of $452 million; EPS of $1.59, up 9% from the fourth quarter of 2024. Full fiscal year 2025 Revenue of $6.95 billion for the fiscal year ended October 31, 2025, exceeding revenue guidance and representing growth of 6.7% on a reported basis and up 4.9% on a c

    11/24/25 4:10:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials